Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

181 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease.
Annereau M, Willekens C, El Halabi L, Chahine C, Saada V, Auger N, Danu A, Bermudez E, Lazarovici J, Ghez D, Leary A, Pistilli B, Lemare F, Solary E, de Botton S, Desmaris RP, Micol JB. Annereau M, et al. Among authors: de botton s. Leuk Res. 2017 Apr;55:58-64. doi: 10.1016/j.leukres.2017.01.024. Epub 2017 Jan 20. Leuk Res. 2017. PMID: 28131982
Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.
Willekens C, Rahme R, Duchmann M, Vidal V, Saada V, Broutin S, Delahousse J, Renneville A, Marceau A, Clappier E, Uzunov M, Rossignol J, Pascal L, Simon L, Micol JB, Pasquier F, Raffoux E, Preudhomme C, Quivoron C, Itzykson R, Penard-Lacronique V, Paci A, Fenaux P, Attar EC, Frattini M, Braun T, Ades L, De Botton S. Willekens C, et al. Among authors: de botton s. Leuk Lymphoma. 2021 Feb;62(2):438-445. doi: 10.1080/10428194.2020.1832661. Epub 2020 Oct 12. Leuk Lymphoma. 2021. PMID: 33043739
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights.
Martin JE, Khalife-Hachem S, Grinda T, Kfoury M, Garciaz S, Pasquier F, Vargaftig J, Uzunov M, Belhabri A, Bertoli S, Cotteret S, Vergé V, Renneville A, Rosselli F, Antony-Debre I, Rouleau E, Salviat F, Caron O, Delaloge S, Pautier P, Etienne G, Recher C, Vey N, De Botton S, Leary A, Marzac C, Micol JB. Martin JE, et al. Among authors: de botton s. Ann Oncol. 2021 Aug;32(8):1046-1048. doi: 10.1016/j.annonc.2021.04.015. Epub 2021 Jun 6. Ann Oncol. 2021. PMID: 34107346 Free article. No abstract available.
Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia.
de Labarthe A, Pautas C, Thomas X, de Botton S, Bordessoule D, Tilly H, de Revel T, Bastard C, Preudhomme C, Michallet M, Fenaux P, Bastie JN, Socié G, Cordonnier C, Dombret H; Acute Leukemia French Association. de Labarthe A, et al. Among authors: de botton s, de revel t. Bone Marrow Transplant. 2005 Apr;35(8):767-73. doi: 10.1038/sj.bmt.1704884. Bone Marrow Transplant. 2005. PMID: 15735660 Clinical Trial.
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).
Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A, Raffoux E, Leblanc T, Thomas X, Hermine O, Quesnel B, Baruchel A, Leverger G, Dombret H, Preudhomme C; Acute Leukemia French Association (ALFA); Leucémies Aiguës Myéloblastiques de l'Enfant (LAME) Cooperative Groups. Boissel N, et al. Among authors: de botton s. Leukemia. 2006 Jun;20(6):965-70. doi: 10.1038/sj.leu.2404188. Leukemia. 2006. PMID: 16598313
181 results